← Back to all trials
Not Yet Recruiting
NCT07862569
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
Conditions: HIV-1, HIV Infection
Sex: All
Ages: N/A – 18 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 45
Sponsor: Merck Sharp & Dohme LLC
Summary
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) \[MK-8591A\] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Eligibility Criteria
Inclusion Criteria:
* Pediatric participant with HIV-1 \
Source: ClinicalTrials.gov (NCT07862569). StuddyBuddy aggregates publicly available trial information.
